Last reviewed · How we verify
Noiiglutide Injection
Noiiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve blood glucose control.
Noiiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve blood glucose control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Noiiglutide Injection |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Noiiglutide binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, contributing to improved glycemic control and potential weight reduction in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
Key clinical trials
- The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients (PHASE3)
- A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects. (PHASE2)
- The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |